Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5339454
Sixty-eight evaluable patients with unresectable adenocarcinoma and large cell carcinoma of the lung were treated on a prospective randomized trial comparing thoracic radiation therapy (TRT) plus combination chemotherapy with either cyclophosphamide, Adriamycin and cis-platinum (CAP) or cyclophosphamide, Adriamycin (same dosages) and DTIC (CAD), 34 on each arm. Patients treated with TRT plus CAP had a better overall regression rate (59% vs 47%) and a statistically significant superiority in time to disease progression (147 days vs 303 days) and survival (217 days vs 504 days).
Research Organization:
Mayo Clinic, Rochester, MN
OSTI ID:
5339454
Conference Information:
Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 5:8
Country of Publication:
United States
Language:
English

Similar Records

Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy
Journal Article · Tue Jul 01 00:00:00 EDT 1980 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:7029379

Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival
Journal Article · Fri Jun 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22056385

Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report
Journal Article · Wed Oct 31 23:00:00 EST 1984 · J. Clin. Oncol.; (United States) · OSTI ID:5615336